All In Biotech

Drug Trial Radar · NCT06438978

Tuberculosis Vaccine in Healthy Indian Adults

An Open-Labelled, Phase I Clinical Trial to Assess the Safety Reactogenicity, Tolerability and Immunogenicity of a Tuberculosis Vaccine BBV169 (MTBVAC), in Healthy Indian Adults

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 19, 2024

Primary completion

Jan 29, 2024

Study completion Jul 27, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An Open-labelled, Phase I Clinical Trial to Assess the Safety, Reactogenicity, Tolerability, and Immunogenicity of MTBVAC in healthy Indian adult volunteers A total of 30 subjects with Quantiferon®-TB Gold Plus assay negative and ages 18 to 65 years will be enrolled in this trial. All the subjects will receive a single dose of MTBVAC via the intradermal route in the right deltoid region. DSMB meetings will be conducted after Day 28 , Day 90 \& Day 180 after vaccinating all subjects.

Conditions

  • Tuberculosis

Interventions

  • Tuberculosis VaccineBiological

    1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain 2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate 3. Lyophilized pellet in vials (10doses) 4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and reactogenicity of MTBVAC Immediate reactionTime frame: 30 Minutes of vaccination.
  2. To evaluate the safety and reactogenicity of MTBVAC-Solicited adverse eventsTime frame: 14 days
  3. To evaluate the safety and reactogenicity of MTBVAC-injection site reactionsTime frame: 90 Days
  4. To evaluate the safety and reactogenicity of MTBVAC-unsolicited adverse eventsTime frame: Through out the trial duration till Day180 Days
  5. To evaluate the safety and reactogenicity of MTBVAC-Serious Adverse Events (SAEs)Time frame: Through out the trial duration till Day180 Days
  6. To evaluate the safety and reactogenicity of MTBVAC-AESI (Adverse Event of Special Interest)Time frame: Through out the trial period till Day180 Days
  7. To evaluate the safety and reactogenicity of MTBVAC-Hematological safety test levels before and after vaccinationTime frame: before and after vaccination on Day 0
  8. To evaluate the safety and reactogenicity of MTBVAC-Biochemical safety test levels before and after vaccinationTime frame: before and after vaccination on Day 0

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NIMS, Hyderabad

    Hyderabad, Telangana, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.